Persistence of the treatment effect of idebenone in Leber’s hereditary optic neuropathy

T. Klopstock,1 G. Metz,2 P. Yu-Wai-Man,3,4 B. Büchner,1 C. Gallenmüller,1 M. Bailie,3,4 N. Nwali,3,4 P. G. Griffiths, 3,4 B. von Livonius,5 L. Reznicek,5 J. Rouleau,6 N. Coppard,2 T. Meier2 and P. F. Chinnery3,4

1 Department of Neurology, Friedrich-Baur-Institute, Ludwig-Maximilians-University, 80336 Munich, Germany
2 Santhera Pharmaceuticals, 4410 Liestal, Switzerland
3 Departments of Neurology and Ophthalmology, Newcastle upon Tyne Foundation Hospital NHS Foundation Trust, NE1 4LP UK
4 Institute of Genetic Medicine, Newcastle University, Newcastle upon Tyne, NE1 3BZ, UK
5 Department of Ophthalmology, Ludwig-Maximilians-University, Munich 80336, Germany
6 Department of Ophthalmology, Centre Hospitalier de l’Université de Montréal (CHUM), Montreal, Quebec H2L 4M1, Canada

Correspondence to: Patrick F. Chinnery, Institute of Genetic Medicine, Newcastle University, Central Parkway, Newcastle upon Tyne, NE1 3BZ, UK
E-mail: p.f.chinnery@newcastle.ac.uk

Correspondence may also be addressed to: Thomas Klopstock, Department of Neurology, Friedrich-Baur-Institute, Ludwig-Maximilians-University, Munich, Germany. E-mail: thomas.klopstock@med.uni-muenchen.de

Sir, There is a growing body of evidence supporting the beneficial effects of idebenone in Leber’s hereditary optic neuropathy (LHON, MIM 353500), an inherited mitochondrial disease that causes rapid bilateral vision loss and lifelong legal blindness. Until recently, reports were limited to isolated case studies and small open-label case series (Mashima et al., 1992, 2000; Cortelli et al., 1997; Carelli et al., 1998, 2001; Barnils et al., 2007). However, in 2011, two articles published in Brain provided additional evidence for the therapeutic use of idebenone in LHON (Carelli et al., 2011; Klopstock et al., 2011).

In the first complete randomized, placebo-controlled, double-blind clinical trial in LHON [Rescue of Hereditary Optic Disease Outpatient Study (RHODOS), ClinicalTrials.gov identifier: NCT00747487], 85 unselected patients with LHON ≥14 years of age were randomized to receive 900 mg/day of idebenone or placebo in a 2:1 ratio for 24 weeks (Klopstock et al., 2011). In the intent-to-treat population, visual acuity data were available for 82 patients harbouring one of the three primary mitochondrial DNA mutations (m.11778G>A, m.3460G>A and m.14484T>C) and experiencing first vision loss up to 5 years before study enrolment. All visual acuity end-points in the intent-to-treat population showed a consistent trend, with idebenone protecting patients from further vision loss, in contrast to the placebo group where visual acuity continued to deteriorate. Efficacy seen on visual acuity end-points was supported by independent measures including tests of colour contrast sensitivity. Following a pre-specified analysis by mutation, exclusion of patients with the m.14484T>C mutation, which is known for its high spontaneous recovery rate, resulted in a larger treatment effect in all visual acuity end-points. This finding was in agreement with the data from a retrospective analysis of 103 patients, published in the same issue of Brain (Carelli et al., 2011). This study showed a significant difference in the incidence of visual recovery in idebenone-treated patients harbouring the m.11778G>A mitochondrial DNA mutation, known to cause ~70% of LHON cases in Europe, and concluded that an early treatment start is recommended.

Vision loss in LHON is rapid, and in the majority of cases results in persistent lifelong visual impairment, typically rendering patients legally blind. Therefore, in light of the relatively short treatment duration of 24 weeks for RHODOS, we have now determined whether the observed treatment effects persisted after...
discontinuation of treatment. For this, we invited patients previously participating in RHODOS for reassessment of their visual acuity to a single visit observational follow-up study (RHODOS–OFU), which had ethical and institutional review board approval and was sponsored by Santhera Pharmaceuticals (ClinicalTrials.gov identifier: NCT01421381). According to the study protocol, the primary end-point was the change in best (logMAR) visual acuity at this study visit compared with baseline and Week 24 of RHODOS.

Sixty patients (70.6%) who participated in RHODOS were enrolled into this RHODOS–OFU study, of whom 58 patients provided visual acuity data in both studies and were included in the analysis. Of these, 39 patients had been randomized to idebenone in the course of RHODOS and 19 patients to placebo, in keeping with the 2:1 ratio of idebenone:placebo in the RHODOS study design. There were no significant differences in the demographics or molecular genetic characteristics of the RHODOS–OFU group compared with the original RHODOS cohort (Table 1), indicating that the smaller subpopulation recruited to the RHODOS–OFU study was representative of the RHODOS study population. The mean ± SD time that had elapsed between Week 24 of RHODOS and the RHODOS–OFU study visit was 30.5 ± 4.9 months (median: 30.1 months). The time since onset of vision loss at baseline of RHODOS for this subpopulation was 23 ± 17 months (median: 18 months).

The change in best visual acuity from Week 24 of RHODOS to the follow-up visit did not correlate with the time elapsed (Spearman’s correlation coefficient = −0.045; P = 0.73) for the patients in this study. Therefore, the RHODOS–OFU visit was treated as a single categorical event in all statistical analyses, and for illustration purposes, the median time elapsed since the end of RHODOS (30 months = 131 weeks) is shown (Fig. 1). The change in best visual acuity during the RHODOS treatment period up to Week 24 was very similar in the subpopulation of this study (n = 58) when compared with the outcome of this end-point in the intent-to-treat population of RHODOS (n = 82). Specifically, the mean difference in best visual acuity estimated by the mixed model of repeated measures for patients randomized to idebenone compared with patients receiving placebo was logMAR −0.120 (six letters; P = 0.078; Fig. 2C in Klopopst et al., 2011) for the RHODOS intent-to-treat population, compared with logMAR −0.175 (eight letters; P = 0.084; Fig. 1, top panel and Table 2) for the patients in the RHODOS–OFU study. This indicates that the 58-patient subgroup is representative of the Week 24 outcome of the RHODOS intent-to-treat population, both in terms of demographics and visual acuity end-points.

Between Week 24 of RHODOS and the RHODOS–OFU visit 30 months later, best visual acuity followed parallel trajectories resulting in a non-significant trend towards improvement (logMAR −0.08; four letters; Fig. 1, top panel) in each of the treatment groups, with no difference between groups (logMAR 0.002; P = 0.982; Table 2). Interestingly, this improvement in best visual acuity between the end of RHODOS and the RHODOS–OFU visit was confined primarily to patients with short disease history irrespective of treatment group (disease onset at RHODOS baseline <1 year, idebenone: logMAR −0.155, placebo: −0.198; disease onset >1 year: idebenone: −0.038, placebo: −0.054). The observed improvement in best visual acuity after discontinuation of the RHODOS treatment period may, at least in part, result from patients learning to use peripheral (extrafoveal) vision. The parallel trajectories after the end of RHODOS led to a mean difference of logMAR −0.173 (eight letters improvement, P = 0.085) in best visual acuity between treatment groups for the entire period from baseline of RHODOS to the RHODOS–OFU visit, which is comparable with the difference observed at Week 24 (logMAR −0.175, see previous text). Thus, the treatment

| Table 1 Demographics of patients enrolled in the RHODOS study compared with the RHODOS observational follow-up study |
|-------------------------------------------------|-----------------|-----------------|
| Parameter                                        | RHODOS Study     | RHODOS–OFU Study |
| Population, n (%)                               | Idebenone | Placebo | Total | Idebenone* | Placebo* | Total |
| Male, n (%)                                      | 47 (85.5) | 26 (86.7) | 73 (85.9) | 34 (87.2) | 16 (84.2) | 50 (88.2) |
| Age in years, mean ± SD (median), (range)       | 33.8 ± 14.8 | 33.6 ± 14.6 | 33.7 ± 14.6 | 34.4 ± 15.3 | 31.5 ± 14.2 | 33.4 ± 14.9 |
| Time since onset in months, mean ± SD (median), (range) | 22.8 ± 16.2 (17.8) (3–62) | 23.7 ± 16.4 (19.2) (2–57) | 23.1 ± 16.2 (18.2) (2–62) | 22 ± 16 (18) (3–60) | 25 ± 18 (19) (2–57) | 23 ± 17 (18) (2–60) |
| Patients with m.11778G>A or m.3460G>A, n (%)    | 44 (80.0) | 24 (80.0) | 68 (80.0) | 33 (84.6) | 17 (89.5) | 50 (86.2) |
| Onset of vision loss within 1 year, n (%)       | 19 (34.5) | 11 (36.7) | 30 (35.3) | 16 (41.0) | 6 (31.6) | 22 (37.9) |
| Patients with both eyes off-chart, n (%)        | 25 (47.2) | 13 (44.8) | 38 (46.3) | 18 (46.2) | 8 (42.1) | 26 (44.8) |
| Eyes off-chart, n (%)                           | 61 (57.5) | 29 (50.0) | 90 (54.9) | 44 (56.4) | 19 (50.0) | 63 (54.3) |
| Best eye visual acuity at BL, mean ± SD (logMAR) | 1.61 ± 0.64 | 1.57 ± 0.61 | 1.59 ± 0.62 | 1.56 ± 0.70 | 1.51 ± 0.64 | 1.55 ± 0.68 |
| Worst eye visual acuity at BL, mean ± SD (logMAR) | 1.89 ± 0.49 | 1.79 ± 0.44 | 1.86 ± 0.47 | 1.89 ± 0.54 | 1.81 ± 0.41 | 1.86 ± 0.50 |
| Both eyes visual acuity at BL, mean ± SD (logMAR) | 1.75 ± 0.58 | 1.68 ± 0.54 | 1.73 ± 0.57 | 1.72 ± 0.64 | 1.66 ± 0.55 | 1.70 ± 0.61 |

a Former treatment group in RHODOS study.
b Percentage RHODOS–OFU population relative to the corresponding group from the RHODOS intent-to-treat population.
c At RHODOS baseline.
d For RHODOS based on efficacy population, n = 82 (53 idebenone, 29 placebo).
e Off-chart defined as >logMAR 1.68 and applying logMAR 2.0/2.3/2.6 for counting fingers/hand motion/light perception.
BL = baseline.
effect observed after 24 weeks of idebenone was maintained long after therapy was terminated. The difference between treatment groups was larger in an analysis for patients carrying either the m.11778G>A or m.3460G>A mutation (i.e. excluding patients with the m.14484T>C mutation). Here, the mean difference between idebenone and placebo-treated patients between the baseline of RHODOS and the RHODOS–OFU visit was logMAR −0.216 (10 letters, \( P = 0.0499 \)).

For the analysis of best recovery of visual acuity, the primary end-point of the RHODOS study, there was a logMAR −0.147 (seven letters, \( P = 0.004 \)) improvement between Week 24 of RHODOS and RHODOS–OFU in the idebenone group compared...
Table 2 Visual acuity outcomes

| Visual acuity analysis | Estimated Differencea ± SEM (95% CI) [difference in letters], P-value |
|------------------------|-------------------------------------------------------------------------|
| Change in best visual acuity |                                                                 |
| Efficacy population  |                                                                 |
| (n = 58: idebenone n = 39, placebo n = 19) | −0.175 ± 0.101 (−0.375 to 0.024), [8 letters], P = 0.0844 |
| Patients with m.11778G>A or m.3460G>A | −0.192 ± 0.111 (−0.411 to 0.027), [9 letters], P = 0.0855 |
| (n = 50: idebenone n = 33, placebo n = 17) | −0.216 ± 0.109 (−0.432 to 0.000), [10 letters], P = 0.0499 |
| Change in visual acuity of individual eyes |                                                                 |
| Efficacy population  |                                                                 |
| (n = 116: idebenone n = 78, placebo n = 38) | −0.133 ± 0.070 (−0.271 to 0.005), [6 letters], P = 0.0594 |
| Patients with m.11778G>A or m.3460G>A | −0.146 ± 0.077 (−0.297 to 0.005), [7 letters], P = 0.0573 |
| (n = 100: idebenone n = 66, placebo n = 34) | −0.228 ± 0.069 (−0.364 to −0.092), [11 letters], P = 0.0011 |
|                                                                                         | −0.283 ± 0.076 (−0.432 to −0.134), [14 letters], P = 0.0002 |

a Data are estimated mean difference [logMAR] ± SEM (95% confidence interval) between idebenone and placebo group calculated from mixed model of repeated measures. Difference in favour of idebenone is indicated by negative logMAR values and positive letter differences indicate improvement in visual acuity.
b Baseline (BL) and Week 24 in RHODOS.
c OFU = RHODOS–OFU visit (median time since Week 24 of RHODOS: 30 months).

In summary, the results from the single-visit RHODOS–OFU study demonstrated that idebenone, when used within 6 months after RHODOS baseline, continued to improve visual acuity for patients in both the idebenone and the placebo groups. The mean difference in best recovery of visual acuity between treatment groups for the entire period from baseline to the follow-up visit described in this study was logMAR −0.054 (two letters, P = 0.459) improvement in the idebenone group compared with −0.028 (one letter, P = 0.098) in the placebo group. The mean difference in best recovery of visual acuity between treatment groups for the entire period from baseline to the ROHODOS–OFU visit was logMAR −0.158 (1.5 letters, P = 0.086).

In line with the previously described findings, the idebenone treatment effect was maintained for all five patients who participated in the ROHODOS–OFU study, which again indicates the long-term persistence of the ROHODOS treatment effect. For the entire observation period, i.e., from Week 4 to the end of the ROHODOS–OFU visit (mean change logMAR −0.116, five letters, P = 0.045), the trajectory in visual acuity for patients in the placebo group did not change from baseline.

It is known that visual acuity usually stabilizes after an initial decline, and except in very rare cases, visual acuity rarely improves thereafter. This continuous improvement in visual acuity might be offset by further deterioration in the worst affected eye, which might explain the observed difference in visual acuity between treatment groups for the entire period from baseline to the ROHODOS–OFU visit.

In summary, the results from the single-visit RHODOS–OFU study demonstrated that idebenone, when used within 6 months after RHODOS baseline, continued to improve visual acuity for patients in both the idebenone and the placebo groups. The mean difference in best recovery of visual acuity between treatment groups for the entire period from baseline to the follow-up visit described in this study was logMAR −0.054 (two letters, P = 0.459) improvement in the idebenone group compared with −0.028 (one letter, P = 0.098) in the placebo group. The mean difference in best recovery of visual acuity between treatment groups for the entire period from baseline to the ROHODOS–OFU visit was logMAR −0.158 (1.5 letters, P = 0.086).
2011), it is conceivable that the drug preserves or re-establishes retinal ganglion cell function during the acute phase, and thus protects from irreversible retinal ganglion cell loss. This is in keeping with the established hypothesis that, in the acute stage, the decrease in visual acuity in LHON is caused by respiratory chain dysfunction with viable, but inactive, retinal ganglion cells (Howell, 1998). Consequently, the therapeutic potential of idebenone therapy is likely to have the highest impact if therapy is initiated early in the disease at a time when retinal ganglion cell loss is still minimal, as suggested by the data of Carelli et al. (2011).

Mashima et al. (2000) and Carelli et al. (2011) both observed a mean time to recovery of ~17 months while patients were continuously kept on treatment. The results of these studies indicate that prolonged treatment could result in a marked recovery of vision even in patients with established disease and severe visual acuity loss, an observation that was also supported by the recent anecdotal findings of Sabet-Peyman et al. (2012), albeit in one patient. A treatment period >6 months might thus offer additional therapeutic benefit.

Acknowledgements

The authors thank J. Al-Tamami for excellent work as a study nurse and G. Rudolph for support in patient investigations. They also thank Mika Leinonen (4Pharma, Sweden, statistical advisor) for discussion and performing statistical analysis.

Funding

P.F.C. is a Wellcome Trust Senior Fellow in Clinical Science and an NIHR Senior Investigator who receives funding from the Medical Research Council (UK) through the MRC Translational Neuromuscular Centre, the Wellcome Trust Centre for Mitochondrial Research, the UK NIHR Biomedical Research Centre for Ageing and Age-related Disease and Biomedical Research Unit award to the Newcastle upon Tyne Foundation Hospitals NHS Trust. P.Y.-W.-M. is an MRC (UK) Clinician Scientist. Recruiting of patients was supported by use of patient databases; the German network for mitochondrial disorders (mitoNET, 01GM0862), which is funded by the German Ministry of Education and Research (BMBF, Bonn, Germany), and the UK Mitochondrial Disease Cohort, which is funded by the Medical Research Council (UK). T.K. is the coordinator of mitoNET, and also receives other funding from the German Ministry of Education and Research and from the Deutsche Forschungsgemeinschaft (DFG).

References

Barnils N, Mesa E, Munoz S, Ferrer-Artola A, Arruga J. Response to idebenone and multivitamin therapy in Leber’s hereditary optic neuropathy. Arch Soc Esp Oftalmol 2007; 82: 377–80.
Carelli V, Barboni P, Zacchini A, Mancini R, Monari L, Cevoli S, et al. Leber’s hereditary optic neuropathy (LHON) with 14484/ND6 mutation in a North African patient. J Neurol Sci 1998; 160: 183–8.
Carelli V, La Morgia C, Valentino ML, Rizzo G, Carbonelli M, De Negri AM, et al. Idebenone treatment in Leber’s hereditary optic neuropathy. Brain 2011; 134: e188.
Carelli V, Valentino ML, Liguori R, Meletti S, Vetrugno R, Provini F, et al. Leber’s hereditary optic neuropathy (LHON/11778) with myoclonus: report of two cases. J Neurol Neurosurg Psychiatry 2001; 71: 813–6.
Cortelli P, Montagna P, Pierangeli G, Lodi R, Barbonti P, Liguori R, et al. Clinical and brain bioenergetics improvement with idebenone in a patient with Leber’s hereditary optic neuropathy: a clinical and 31P-MRS study. J Neurol Sci 1997; 148: 25–31.
Haefeli RH, Erb M, Gempferli AC, Robay D, Courdier Fruh I, Ankl C, et al. NQO1-dependent redox cycling of idebenone: effects on cellular redox potential and energy levels. PLoS One 2011; 6: e17963.
Howell N. Leber hereditary optic neuropathy: respiratory chain dysfunction and degeneration of the optic nerve. Vision Res 1998; 38: 1495–504.
Klopstock T, Yu-Wai-Man P, Dimitriadis K, Rouleau J, Heck S, Bailie M, et al. A randomized placebo-controlled trial of idebenone in Leber’s hereditary optic neuropathy. Brain 2011; 134: 2677–86.
Mashima Y, Hida Y, Oguchi Y. Remission of Leber’s hereditary optic neuropathy with idebenone. Lancet 1992; 340: 368–9.
Mashima Y, Kigasawa K, Wakakura M, Oguchi Y. Do idebenone and vitamin therapy shorten the time to achieve visual recovery in Leber hereditary optic neuropathy? J Neuroophthalmol 2000; 20: 166–70.
Sabet-Peyman EJ, Khaderi KR, Sadun AA. Is leber hereditary optic neuropathy treatable? Encouraging results with idebenone in both prospective and retrospective trials and an illustrative case. J Neuroophthalmol 2012; 32: 54–7.